BRPI0918496A2 - composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula - Google Patents
composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célulaInfo
- Publication number
- BRPI0918496A2 BRPI0918496A2 BRPI0918496A BRPI0918496A BRPI0918496A2 BR PI0918496 A2 BRPI0918496 A2 BR PI0918496A2 BR PI0918496 A BRPI0918496 A BR PI0918496A BR PI0918496 A BRPI0918496 A BR PI0918496A BR PI0918496 A2 BRPI0918496 A2 BR PI0918496A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- pharmaceutical composition
- inhibitor compound
- bicyclic
- kinase inhibitor
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9366908P | 2008-09-02 | 2008-09-02 | |
| PCT/EP2009/061182 WO2010026121A1 (en) | 2008-09-02 | 2009-08-31 | Bicyclic kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918496A2 true BRPI0918496A2 (pt) | 2019-09-24 |
Family
ID=41211220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918496A BRPI0918496A2 (pt) | 2008-09-02 | 2009-08-31 | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8735424B2 (enExample) |
| EP (1) | EP2342190A1 (enExample) |
| JP (1) | JP5564045B2 (enExample) |
| KR (1) | KR20110058866A (enExample) |
| CN (1) | CN102203075B (enExample) |
| AU (1) | AU2009289316A1 (enExample) |
| BR (1) | BRPI0918496A2 (enExample) |
| CA (1) | CA2735779A1 (enExample) |
| EA (1) | EA201100426A1 (enExample) |
| MX (1) | MX2011002367A (enExample) |
| WO (1) | WO2010026121A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2474545T (pt) | 2005-12-13 | 2017-02-14 | Incyte Holdings Corp | Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase |
| GEP20125533B (en) | 2007-06-13 | 2012-05-25 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| HRP20192203T1 (hr) | 2009-05-22 | 2020-03-06 | Incyte Holdings Corporation | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| PE20130038A1 (es) | 2010-03-10 | 2013-01-28 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de jak1 |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| KR20140019300A (ko) | 2010-11-19 | 2014-02-14 | 인사이트 코포레이션 | Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체 |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| TWI761825B (zh) | 2012-11-15 | 2022-04-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| PE20151979A1 (es) | 2013-01-23 | 2016-01-15 | Astrazeneca Ab | Compuestos quimicos |
| BR122021015061B1 (pt) | 2013-03-06 | 2022-10-18 | Incyte Holdings Corporation | Processos e intermediários para preparar um inibidor de jak |
| WO2015021153A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| CL2015001657S1 (es) | 2014-12-15 | 2016-09-02 | Jjgc Indústria E Comércio De Materiais Dentários S A | Configuracion aplicada a implante oseo. |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
| WO2017019723A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
| WO2017019724A1 (en) | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| HUE066591T2 (hu) * | 2015-12-17 | 2024-08-28 | Merck Patent Gmbh | 8-ciano-5-piperidino-kinolinok, mint TLR7/8 antagonisták és alkalmazásuk immunrendellenességek kezelésére |
| NZ750174A (en) | 2016-07-14 | 2023-04-28 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| CN105974036A (zh) * | 2016-07-31 | 2016-09-28 | 合肥远志医药科技开发有限公司 | 一种氨基吡啶异构体的检测方法 |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| PL3773593T3 (pl) | 2018-03-30 | 2024-09-02 | Incyte Corporation | Leczenie ropnego zapalenia gruczołów potowych z zastosowaniem inhibitorów jak |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| US12258343B2 (en) * | 2018-08-24 | 2025-03-25 | Bayer Aktiengesellschaft | Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| IL301038A (en) | 2020-09-09 | 2023-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulator formulations |
| WO2022090101A1 (en) | 2020-10-26 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Process for synthesis of 2,4-dichloro-5-aminopyrimidine |
| US20240092800A1 (en) * | 2021-01-14 | 2024-03-21 | Georgetown University | Usp13 inhibitors and methods of use thereof |
| CN113648294B (zh) * | 2021-08-26 | 2024-01-23 | 山东领海生物科技有限公司 | β-双磺酰亚胺取代酮类化合物在治疗癌症中的应用 |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
| WO2024186839A1 (en) * | 2023-03-05 | 2024-09-12 | University Of Vermont And State Agricultural College | Bicyclic aryl sulfonamides, sulfones, and sulfonate esters as anti-parasitic agents |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) * | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| DE3815617A1 (de) | 1988-05-07 | 1989-11-16 | Bayer Ag | 4-aza-1,10-phenanthrolin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung in schaedlingsbekaempfungsmitteln |
| US5204472A (en) | 1990-04-06 | 1993-04-20 | Bayer Aktiengesellschaft | Quinoline and isoquinoline intermediates |
| DE4011105A1 (de) * | 1990-04-06 | 1991-10-10 | Bayer Ag | Neue 4-chinolyl-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| ES2186908T3 (es) * | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| WO2004018419A2 (en) * | 2002-08-23 | 2004-03-04 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US7692011B2 (en) * | 2002-10-04 | 2010-04-06 | Prana Biotechnology Limited | 8-hydroxy and 8-mercapto quinazolinones |
| EP1667979A4 (en) | 2003-09-23 | 2007-04-18 | Merck & Co Inc | ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| JP2006219453A (ja) * | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| CA2612788A1 (en) | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| WO2010026124A1 (en) * | 2008-09-02 | 2010-03-11 | Novartis Ag | Picolinamide derivatives as kinase inhibitors |
-
2009
- 2009-08-31 KR KR1020117007560A patent/KR20110058866A/ko not_active Withdrawn
- 2009-08-31 CA CA2735779A patent/CA2735779A1/en not_active Abandoned
- 2009-08-31 BR BRPI0918496A patent/BRPI0918496A2/pt not_active IP Right Cessation
- 2009-08-31 AU AU2009289316A patent/AU2009289316A1/en not_active Abandoned
- 2009-08-31 EP EP09782373A patent/EP2342190A1/en not_active Withdrawn
- 2009-08-31 CN CN200980143219.4A patent/CN102203075B/zh not_active Expired - Fee Related
- 2009-08-31 MX MX2011002367A patent/MX2011002367A/es not_active Application Discontinuation
- 2009-08-31 US US13/060,971 patent/US8735424B2/en active Active
- 2009-08-31 WO PCT/EP2009/061182 patent/WO2010026121A1/en not_active Ceased
- 2009-08-31 JP JP2011524403A patent/JP5564045B2/ja not_active Expired - Fee Related
- 2009-08-31 EA EA201100426A patent/EA201100426A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011002367A (es) | 2011-04-04 |
| AU2009289316A1 (en) | 2010-03-11 |
| JP2012501312A (ja) | 2012-01-19 |
| CA2735779A1 (en) | 2010-03-11 |
| EA201100426A1 (ru) | 2011-10-31 |
| WO2010026121A1 (en) | 2010-03-11 |
| EP2342190A1 (en) | 2011-07-13 |
| US20110195980A1 (en) | 2011-08-11 |
| KR20110058866A (ko) | 2011-06-01 |
| CN102203075B (zh) | 2014-09-10 |
| US8735424B2 (en) | 2014-05-27 |
| CN102203075A (zh) | 2011-09-28 |
| JP5564045B2 (ja) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918496A2 (pt) | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula | |
| BRPI0908637A2 (pt) | composto; composição farmacêutica do mesmo e método para inibição de proliferação celular em um indivíduo. | |
| SMT201400154B (it) | Composti di triazolopiridina come inibitori di chinasi pim | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0914599A2 (pt) | métodos para tratar ou prevenir câncer, para inibir uma pim quinase, e para fabricar um composto, composto, composição farmacêutico, e, uso de um composto | |
| BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
| BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
| BRPI0817681A2 (pt) | Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase | |
| BRPI0923384A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular | |
| IL211018A (en) | Inhibitors, processes for making them, medicinal preparations containing them and their use | |
| BRPI0807146A2 (pt) | Inibidores da atividade da akt | |
| ZA201101586B (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
| BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
| BRPI0918359A2 (pt) | composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto | |
| BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
| BRPI0908565A2 (pt) | composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase | |
| BRPI0920261A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica | |
| BRPI0907608A2 (pt) | Formulas dinâmicas para células de planilha | |
| BRPI0813306A2 (pt) | composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto. | |
| PT2368118E (pt) | Biomarcadores para inibidores com atividade anti-angiogénica | |
| BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
| EP2239261A4 (en) | PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF | |
| BRPI0720604A8 (pt) | composição e método para detecção de desmineralização | |
| BRPI0817396A2 (pt) | Método para tratar deficiência de vitamina b12 num indivíduo e composição farmacêutica para tratar deficiência de vitamina b12 num individuo | |
| IL212755A0 (en) | Pyrazinopyrazines and derivatives as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |